论文部分内容阅读
目的探讨乳腺肿瘤激酶(breast tumorkinase,Brk)在非小细胞肺癌(non-small cell lungcancer,NSCLC)的表达及与临床病理因素,Ki67表达之间的关系。方法采用免疫组织化学S-P法检测105例NSCLC及相应癌旁正常肺组织中Brk和Ki67的表达,采用Western Blot方法检测30例新鲜肺癌组织及其癌旁正常肺组织中Brk的表达情况。结果 Western Blot结果显示NSCLC中Brk蛋白表达水平显著高于癌旁正常肺组织(P<0.01)。免疫组织化学结果发现Brk在NSCLN的细胞浆阳性率为51.4%(54/105),明显高于其在癌旁正常肺组织的细胞浆阳性率18.1%(19/105,P=0.003)。Brk在NSCLC细胞浆的阳性表达与肿瘤的大小(P=0.042),淋巴结转移(P=0.012),TNM分期(P=0.042)正相关;Ki67的表达与肿瘤的大小正相关(P=0.033);Brk在细胞浆中的表达与Ki67表达呈正相关(r=0.217,P=0.026)。结论 Brk在NSCLC的细胞表达上调,与肿瘤大小,淋巴结转移,TNM分期正相关;Ki67表达与肿瘤的大小正相关;Brk与Ki67的协同表达可能是促进NSCLC进展的重要因素。
Objective To investigate the expression of breast tumor kinase (Brk) in non-small cell lung cancer (NSCLC) and its relationship with clinical pathological factors and Ki67 expression. Methods The expressions of Brk and Ki67 in 105 cases of NSCLC and its adjacent normal lung tissues were detected by immunohistochemical S-P method. The expression of Brk in 30 fresh lung cancer tissues and adjacent normal lung tissues was detected by Western Blot. Results The results of Western Blot showed that the expression of Brk protein in NSCLC was significantly higher than that in normal lung tissue (P <0.01). Immunocytochemistry results showed that the positive rate of Brk in cytoplasm of NSCLN was 51.4% (54/105), which was significantly higher than that in Bcl-2 normal lung tissue (18.1%, 19/105, P = 0.003). The positive expression of Brk in cytoplasm of NSCLC was positively correlated with tumor size (P = 0.042), lymph node metastasis (P = 0.012) and TNM stage (P = 0.042) The expression of Brk in cytoplasm was positively correlated with the expression of Ki67 (r = 0.217, P = 0.026). Conclusion The up-regulation of Brk expression in NSCLC is positively correlated with tumor size, lymph node metastasis and TNM stage. Ki67 expression is positively correlated with tumor size. The synergistic expression of Brk and Ki67 may play an important role in the progression of NSCLC.